These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11446525)

  • 21. Antimicrobial Therapy for Pneumonia in the Emergency Department: The Impact of Clinical Pharmacists on Appropriateness.
    Faine BA; Mohr N; Dietrich J; Meadow L; Harland KK; Chrischilles E
    West J Emerg Med; 2017 Aug; 18(5):856-863. PubMed ID: 28874937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of the efficiency of antimicrobial treatment for community-acquired pneumonia in clinical practice].
    Zhukova OV; Ruina OV; Kononova SV; Konyshkina TM
    Ter Arkh; 2017; 89(8):17-21. PubMed ID: 28914846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implication of clinical pathway care for community-acquired pneumonia in a community hospital: early switch from an intravenous beta-lactam plus a macrolide to an oral respiratory fluoroquinolone.
    Shindo Y; Sato S; Maruyama E; Ohashi T; Ogawa M; Imaizumi K; Hasegawa Y
    Intern Med; 2008; 47(21):1865-74. PubMed ID: 18981629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Importance of atypical pathogens of community-acquired pneumonia.
    Plouffe JF
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S35-9. PubMed ID: 10984326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia.
    Najib MM; Stein GE; Goss TF
    Pharmacotherapy; 2000 Apr; 20(4):461-9. PubMed ID: 10772376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.
    File TM; Tan JS
    Drugs; 2003; 63(2):181-205. PubMed ID: 12515565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
    Weiss K; Tillotson GS
    Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergency management of community-acquired bacterial pneumonia: what is new since the 2007 Infectious Diseases Society of America/American Thoracic Society guidelines.
    Moran GJ; Rothman RE; Volturo GA
    Am J Emerg Med; 2013 Mar; 31(3):602-12. PubMed ID: 23380120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous/oral sequential therapy in patients hospitalised with community-acquired pneumonia: which patients, when and what agents?
    Vogel F
    Drugs; 2002; 62(2):309-17. PubMed ID: 11817975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Community-acquired pneumonia.
    Bartlett JG
    Int J Clin Pract Suppl; 2000 Dec; (115):18-22. PubMed ID: 11219294
    [No Abstract]   [Full Text] [Related]  

  • 31. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
    Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D
    Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
    Feagan BG
    Pharmacotherapy; 2001 Jul; 21(7 Pt 2):89S-94S. PubMed ID: 11446524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of treatment guidelines for community-acquired pneumonia.
    Niederman MS
    Am J Med; 2004 Aug; 117 Suppl 3A():51S-57S. PubMed ID: 15360097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database.
    Brown RB; Iannini P; Gross P; Kunkel M
    Chest; 2003 May; 123(5):1503-11. PubMed ID: 12740267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managing antiinfective therapy of community-acquired pneumonia in the hospital setting: focus on switch therapy.
    Ramirez JA
    Pharmacotherapy; 2001 Jul; 21(7 Pt 2):79S-82S. PubMed ID: 11446522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study.
    Gotfried M; Quinn TC; Gothelf S; Wikler MA; Webb CD; Nicholson SC
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):85-91. PubMed ID: 12376037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sparfloxacin: a review.
    Schentag JJ
    Clin Ther; 2000 Apr; 22(4):372-87; discussion 371. PubMed ID: 10823360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Total duration of antimicrobial therapy in veterans hospitalized with uncomplicated pneumonia: Results of a national medication utilization evaluation.
    Madaras-Kelly KJ; Burk M; Caplinger C; Bohan JG; Neuhauser MM; Goetz MB; Zhang R; Cunningham FE;
    J Hosp Med; 2016 Dec; 11(12):832-839. PubMed ID: 27527659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA; Ehrhardt AF; Jones RN
    Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Community-acquired pneumonia: the evolving challenge.
    Finch R
    Clin Microbiol Infect; 2001; 7 Suppl 3():30-8. PubMed ID: 11523560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.